Nonetheless, CXCL8, CXCL10, and CCL5, along with their corresponding receptors (CXCR1 and CXCR2), CXCR3, and CCR5, respectively [96,97], appear to be a promising therapeutic target for preventing ASMC migration in bronchial remodeling and, as a result, exacerbation of the disease in patients with chronic lung conditions, such as asthma and COPD. The gene discussed is CCL5; the disease is asthma.